Thermo Fisher Scientific agrees companion diagnostics deal with Blueprint Medicines

Thermo Fisher Scientific has announced a new oncology companion diagnostic development agreement with Blueprint Medicines.

This deal will see Thermo Fisher Scientific develop and commercialise its Oncomine Dx target test as a companion diagnostic for the new RET inhibitor therapy called BLU-667, which is being developed as a treatment for non-small cell lung cancer (NSCLC).

RET fusions are believed to be key disease drivers in about one to two percent of patients with NSCLC, so the test will be used to identify patients with these mutations in order to determine which individuals will respond best to treatment with BLU-667.

Blueprint Medicines has already begun a phase I clinical trial of the drug, with the new companion test complementing efforts to drive enrolment. Once validation is complete, Thermo Fisher will seek approval from the US Food and Drug Administration (FDA) for the test.

Joydeep Goswami, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific, said: "We are pleased to work with Blueprint Medicines and leverage the expandability of the FDA-approved Oncomine Dx Target Test to offer it as a companion diagnostic for BLU-667."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.